LUND, Sweden & PARIS--(BUSINESS WIRE)--Regulatory News: Active Biotech (NASDAQ OMX NORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) (Paris:IPN) today announced that Active Biotech, under the terms of the co-development and commercialization agreement on the novel candidate drug tasquinimod, has received a milestone payment of 12 million euros from Ipsen.
Help employers find you! Check out all the jobs and post your resume.
